Cystic Fibrosis: License agreement boosts development of therapy against lung infections
21-Dec-2007 -
Axentis Pharma AG (Switzerland) and aRigen Pharmaceuticals, Inc. (Japan) announced the signature of a license agreement for the development of therapy against lung infections in Cystic Fibrosis patients. Under the terms of the agreement Axentis Pharma AG purchased from aRigen Pharmaceuticals, ...
clinical trials
cystic fibrosis
drug delivery
+6